HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.

AuthorsL Sokol, L Cripe, H Kantarjian, M A Sekeres, S Parmar, P Greenberg, S L Goldberg, V Bhushan, J Shammo, R Hohl, A Verma, G Garcia-Manero, Y-P Li, A Lowe, J Zhu, A F List
JournalLeukemia (Leukemia) Vol. 27 Issue 4 Pg. 977-80 (Apr 2013) ISSN: 1476-5551 [Electronic] England
PMID23032694 (Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Letter, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Indoles
  • Protein Kinase Inhibitors
  • SCIO-469
  • Mitogen-Activated Protein Kinase 14
Topics
  • Aged
  • Aged, 80 and over
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Indoles (pharmacology, therapeutic use)
  • Male
  • Middle Aged
  • Mitogen-Activated Protein Kinase 14 (antagonists & inhibitors)
  • Myelodysplastic Syndromes (drug therapy)
  • Protein Kinase Inhibitors (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: